ID: ALA3618495

Max Phase: Preclinical

Molecular Formula: C55H68O32

Molecular Weight: 1241.12

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(/C=C/C(=O)OC[C@H]2O[C@@H](O[C@H]3[C@H](OC4=C(c5cc(O)c(O[C@@H]6OC[C@@H](O[C@@H]7O[C@@H](C)[C@H](O)[C@@H](O)[C@H]7O)[C@H](O)[C@H]6O)c(O)c5)Cc5cc(O)cc(O)c5C4=O)O[C@@H](C)[C@H](O)[C@H]3O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@@H]2O)ccc1O

Standard InChI:  InChI=1S/C55H68O32/c1-17-34(63)40(69)45(74)52(79-17)82-31-16-78-51(44(73)38(31)67)85-48-26(60)11-20(12-27(48)61)23-10-21-9-22(57)13-25(59)33(21)39(68)47(23)84-54-49(42(71)35(64)18(2)80-54)87-55-50(86-53-46(75)41(70)36(65)29(14-56)81-53)43(72)37(66)30(83-55)15-77-32(62)7-5-19-4-6-24(58)28(8-19)76-3/h4-9,11-13,17-18,29-31,34-38,40-46,49-61,63-67,69-75H,10,14-16H2,1-3H3/b7-5+/t17-,18-,29+,30+,31+,34-,35-,36+,37+,38-,40+,41-,42+,43-,44+,45+,46+,49+,50+,51-,52-,53-,54-,55-/m0/s1

Standard InChI Key:  IDIWMCDHBXDAEC-BPQKETPESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1241.12

Molecular Weight (Monoisotopic): 1240.3694

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Al-Asri J, Fazekas E, Lehoczki G, Perdih A, Görick C, Melzig MF, Gyémánt G, Wolber G, Mortier J..  (2015)  From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.,  23  (20): [PMID:26395057] [10.1016/j.bmc.2015.09.007]

Source

Source(1):

• Scientific Literature